[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medically-refractory-epilepsy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medically-refractory-epilepsy":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":40,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":5},"100640275","spatial-scene-recognition-memory-in-epilepsy-surgery-100640275",false,"NCT07580183","Spatial Scene Recognition Memory in Epilepsy Surgery","Investigations of Spatial Recognition Memory to Improve Cognitive Outcomes in Epilepsy Surgery","Inclusion Criteria:\n\n* Age 18 years or older\n* For Aims I and III: Diagnosis of focal epilepsy or temporal lobe lesion; patients undergoing evaluation for or having undergone epilepsy surgery\n* For Aim II: Healthy adult participants\n* Full-Scale IQ ≥ 70\n* English proficiency sufficient to understand and complete the task\n* For Aim I: Enrolled in or eligible for Emory University epilepsy surgery research registry\n* For Aim III: Undergoing clinically indicated stereoelectroencephalography (SEEG) at UC Davis Medical Center\n* Able to provide informed consent (or for Aim I retrospective component, prior consent in Emory registry)\n\nExclusion Criteria:\n\n* Full-Scale IQ \\\u003C 70\n* Inability to provide informed consent\n* For Aim III: Age \\> 55 years\n* For Aim II: History of neurological or psychiatric disorder (as applicable per study protocol)",true,"ALL","18 Years","55 Years",{"count":21,"type":22},620,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study investigates the anatomical and physiological basis of spatial scene recognition memory in patients with temporal lobe epilepsy and temporal lobe lesions. Standard neuropsychological tests are insensitive to important memory deficits experienced by patients, particularly in spatial\u002Fscene memory, recollective experience, and familiarity processing. Using a validated virtual tour paradigm, the study examines how familiarity-based recognition and recall of spatial scenes relate to specific brain structures. In Aim I, a large cohort of patients with varied temporal lobe lesions at Emory University undergoes the virtual tour task with voxel-based lesion-symptom mapping to localize necessary brain regions. In Aim II, scalp event-related potentials and eye tracking in healthy participants at UC Davis characterize the temporal dynamics and lateralization of scene recognition. In Aim III, intracranial EEG recordings (including local field potentials and single-unit activity) in epilepsy surgery patients at UC Davis determine the precise network dynamics underlying spatial scene familiarity and recall. The long-term goal is to improve the prediction and prevention of cognitive morbidity from epilepsy surgery by providing a more complete model of spatial recognition memory circuits.",[28,29,30,31,32,33,34,35,36,37,38,39],"Focal Epilepsy","Temporal Lobe Epilepsy","Medically Refractory Epilepsy","Memory Disorders","Epilepsy Comorbidities","Epilepsy Intractable","Epilepsy Surgery","Epilepsy, Temporal Lobe","Memory Deficits","Memory Disorder, Spatial","Memory Dysfunction","Spatial Perception",[41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64],"spatial memory","recognition memory","familiarity","recollection","neural circuits of memory","phenomenology of memory","scene memory","virtual tour","epilepsy surgery","SEEG","stereo-electroencephalography","lesion-symptom mapping","network-symptom mapping","cognitive electrophysiology","event-related potentials","intracranial EEG","iEEG","parahippocampal gyrus","perirhinal cortex","hippocampus","tetrodes","deja vu","neuropsychology","consciousness","RECRUITING","2026-05-06",{"date":68,"type":69},"2026-05-12","ACTUAL",{"date":71,"type":69},"2024-07-01",{"date":73,"type":22},"2030-06-30",{"name":75,"class":76},"University of California, Davis","OTHER",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100440790","phase-2-the-efficacy-of-a-subanesthetic-doses-of-iv-ketamine-in-the-treatment-drug-resistant-epilepsy-100440790","NCT05019885","The Efficacy of a Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy","A Pilot Study to Assess the Efficacy of Subanesthetic Doses of IV Ketamine in the Treatment Drug Resistant Epilepsy","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Adults (18 years or older)\n* Cognitively impaired adults are not excluded (i.e. will be included in the study)\n* Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs)\n* EEG consistent with focal or generalized epilepsy\n* Patients must have \\>4 focal aware, focal impaired aware, focal to bilateral tonic clonic or generalized tonic clonic seizures per month.\n* Patients can be on \\>\u002F= 1 anti-seizure medication (ASM) at the time of enrollment on stable doses 12 weeks prior to initiation\n* Patients on Epilepsy devices: Vagal nerve stimulator (VNS), Deep brain stimulator (DBS) or Responsive Nerve Stimulator (RNS) must have remained stable for at least 4 weeks before the screening visit. Adjustment of devices is not allowed during the study.\n\nExclusion Criteria\n\n* Patients \\\u003C18 years of age\n* Pregnant women\n* Women that are breast feeding\n* Patients who had \\>21 days of seizure freedom in the last year.\n* Patients with a history of status epilepticus within 3 months of screening\n* Patients with a history of alcoholism of drug misuse within the last 2 years\n* Unstable medical illness\n* Serious or imminent suicidal or homicidal risk\n* Patients with cardiovascular disease\n* Patients with schizophrenia\n* Patients with history of aneurysm or aortic dissection, arteriovenous malformation and intracerebral hemorrhage\n* Patients that are immobile i.e. wheel chair bound, bed ridden individuals\n* Patients on psychostimulants (amphetamines, methylphenidate etc.) and Monoamine oxidase inhibitors (selegiline, isocarboxazid, phenelzine etc.)",{"count":85,"type":22},8,[87],"PHASE2","Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.",[90,30,91],"Drug Resistant Epilepsy","Refractory Epilepsy",[93,94],"drug resistant epilepsy","subanesthetic Ketamine hydrochloride","2025-08-13",{"date":97,"type":69},"2025-08-15",{"date":99,"type":69},"2022-08-26",{"date":101,"type":22},"2026-03",{"name":103,"class":76},"Madeline Fields",1]